Effect of Artemisia vulgaris Extract on Granzyme Expression and Tumor Mass Diameter (Study of Adriamycin Cyclophosphamide Chemotherapy in Adenocarcinoma Mammae C3H Mice Model)
DOI:
https://doi.org/10.21776/ub.jkb.2021.031.04.1Keywords:
Adenocarcinoma mammae, Artemisia vulgaris, granzyme, tumor massAbstract
Breast cancer incident continues to increase globally. The surgical management can be combined with other therapeutic modalities, including chemotherapy, radiation, and immunotherapy, such as Artemisia vulgaris (AV). This study aimed to determine the effect of AV extract on Granzyme expression and tumor mass diameter growth of C3H mice with adenocarcinoma mammae. Twenty-four female C3H mice were randomly divided into groups of K (control), P1 (AC chemotherapy), P2 (AV extract), and P3 (combination). Adenocarcinoma mammae were inoculated from donor mice. Two cycles of chemotherapy by Adriamycin 0.18 mg and Cyclophosphamide 1.8 mg were given intravenously, while Artemisia vulgaris 13 mg (0.2 ml) was given orally once per day. Granzyme expression was assessed using immunohistochemical staining, while tumor mass diameter growth was measured using tumor calipers. There was a significant negative correlation between and tumor mass diameter growth (p=0,001 and r=-0,911). Artemisia vulgaris increases the apoptotic effects of Adriamycin-Cyclophosphamide chemotherapy by increasing Granzyme expression and decreasing tumor mass diameter growth in adenocarcinoma mammae C3H mice.
Downloads
References
Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and Cervical Cancer in 187 Countries between 1980 and 2010: A Systematic Analysis. Lancet. 2011; 378(9801): 1461-84.
Mugi W. Deteksi Dini Kanker Leher Rahim dan Kanker Payudara di Indonesia 2007–2014. In: Kementerian Kesehatan RI (Ed). Buletin Jendela Data dan Informasi Kesehatan. Jakarta: Kementerian Kesehatan Republik Indonesia; 2015: p. 12-15.
Kementerian Kesehatan Republik Indonesia. Panduan Nasional Penanganan Kanker (Kanker Payudara). Jakarta: Komite Nasional Penanggulangan Kanker; 2015: p. 1-10.
Azwardi R. Perkembangan Mutakhir Tumor Ganas Payudara. Universa Medicina. 2005; 24(4): 190-197.
Luangdilok S, Samarnthai N, and Korphaisarn K. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. Journal of Breast Cancer. 2014; 17(4): 376-385.
Das AK. Anticancer Effect of AntiMalarial Artemisinin Compounds. Annals of Medical and Health Sciences research. 2015; 5(2): 93-102.
Haniya AK and Padma PR. Phytochemical Investigation of Methanolic Extract of Artemisia Vulgaris L. Leaves. International Journal of Pharma and Bio Science. 2014; 5(2): 184-195.
Yance DR, Sagar SM. Targeting Angiogenesis with Integrative Cancer Therapies. Integrative Cancer Therapies. 2006; 5(1): 9-29.
Jianguang J, Yiyu Q, Ligong Z, et al. Artemisinin Inhibits Gallbladder Cancer Cell Lines Through Triggering Cell Cycle Arrest and Apoptosis. Molecular Medicine Reports. 2016; 13(5): 4461-8.
Abbas A, Lichtman AH, and Pillai S. Cellular and Molecular Immunology. 6th ed. Philadelphia: Elseiver-Saunders; 2007: p. 3-15, 65-80, 275-289, 314-316, 391-410.
Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicologic Pathology. 2007; 35(4): 495-516.
Houh YK, Kim KE, Park S, et al. The Effects of Artemisinin on the Cytolytic Activity of Natural Killer (NK) Cells. International Journal of Molecular Sciences. 2017; 18(7): 1-11.
Roitt IM and Delves PJ. Roitt's Essential Immunology. 10th edition. Massachusetts: Blackwell Science; 2001: p. 137-139.
Abbas AK, Lichtman AH, and Pillai S. Cellular and Mollecular Immunology. 8th edition. Philadelphia: Saunders Elsevier; 2015: p. 383-397.
Hermawan A and Sarmoko. Doxorubicin Cancer Chemoprevention Research Center Farmasi UGM. (Online) 4 Februari 2011. ccrc.farmasi.ugm.ac.id/?page_id=2246 [diakses tanggal 10 Oktober 2017].
Jankowitz RC and Davidson NE. Breast Cancer. In: Boyiadzis MM, Frame JN, Kohler DR, and Fojo T (Eds). Hematology-Oncology Therapy. 2nd edition. New York: McGraw-Hill Education; 2014: p. 102
Fleming RA. An Overview of Cyclophosphamide and Ifosfamide Pharmacology. Pharmacotherapy. 1997; 17(5): 146-154.
Johnson CR, Thames HD, Huang DT, and Schmidt-Ullrich RK. The Tumor Volume and Clonogen Number Relationship: Tumor Control Predictions Based Upon Tumor Volume Estimates Derived From Computed Tomography. International Journal of Radiation Oncology, Biology, Physics. 1995; 33(2): 281-287.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute. 2000; 92(3): 205–216
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
